Chidan Wan

Chidan Wan


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2022 in Ultrasonics Sonochemistry
Verified
Journal Article
Open access
SSShenchao Shi
Shenchao Shi
RZRuizheng Zhong
Ruizheng Zhong
LLLele Li
Lele Li
CWChidan Wan
Chidan Wan
CWCan Wu
Can Wu
• Two-dimensional graphene@MXene nanohybrid was facilely prepared through ultrasonic liquid-phase exfoliation. • In-situ ultrasound-assisted synthesis of graphene@MXene hybrid suspension exhibited high stability. • Significant synergistic signal enhancement effect was displayed due to the integration of graphene and MXene. • Novel electrochemical sensing platform for the sensitive detection of chlorpromazine and rhodamine B was developed.

1 April 2020 in Analytica Chimica Acta
Verified
Journal Article
Closed access
SSShiran Sun
Shiran Sun
YTYong Tang
Yong Tang
CWCan Wu
Can Wu
CWChidan Wan
Chidan Wan

28 April 2023 in Analytica Chimica Acta
Verified
Journal Article
Closed access
SSShenchao Shi
Shenchao Shi
GCGuojun Cao
Guojun Cao
YCYimeng Chen
Yimeng Chen
JHJingqi Huang
Jingqi Huang
YTYong Tang
Yong Tang
CWCan Wu
Can Wu

1 April 2021 in Analytica Chimica Acta
Verified
Journal Article
Closed access
CCChuxing Chai
Chuxing Chai
JGJuan Gao
Juan Gao
GZGuoqian Zhao
Guoqian Zhao
LLLele Li
Lele Li
YTYong Tang
Yong Tang
CWChidan Wan
Chidan Wan


26 March 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
TWTao Wang
Tao Wang
DWDecai Wang
Decai Wang
RSRuizi Shi
Ruizi Shi
XZXintao Zeng
Xintao Zeng
PYPei Yang
Pei Yang
JWJian jun Wang
Jian jun Wang
This research focused on exploring the association between coagulopathy scores and the survival outcomes, both short-term and long-term, in individuals diagnosed with liver cirrhosis complicated by sepsis. This study retrospectively analyzed data from individuals with liver cirrhosis and sepsis who were admitted to the intensive care unit (ICU) at Beth Israel Deaconess Medical Center between 2008 and 2022. The main outcome of interest was all-cause mortality within 28 days post-admission, while the secondary outcome assessed mortality within 90 days. We used the Kaplan-Meier analysis to compare the mortality risk among the different groups. To evaluate the relationship between coagulopathy score and mortality risk in patients with liver cirrhosis and sepsis, a multivariate Cox proportional hazards regression analysis was performed. The predictive performance of the coagulopathy score for short- and long-term all-cause mortality was assessed using receiver operating characteristic (ROC) curve analysis, which included evaluation of its sensitivity, specificity, and area under the curve. Subgroup analyses were performed to evaluate the relationship between coagulopathy score and survival across different groups. The study included a total of 2,278 patients. Kaplan-Meier survival analysis demonstrated that individuals with elevated coagulopathy scores exhibited markedly higher rates of ICU mortality, in-hospital mortality, as well as 28-day and 90-day mortality, with all log-rank tests yielding P-values of less than 0.001. The results of the multivariate Cox regression analysis showed that an elevated coagulopathy score was independently linked to higher 28-day and 90-day all-cause mortality, both before and after controlling for potential confounders. ROC curve analysis showed that although the coagulopathy score was slightly less predictive of prognosis than the Model for End-stage Liver Disease score, it significantly outperformed the Sequential Organ Failure Assessment score and the Sepsis-induced Coagulopathy score. Subgroup analysis revealed no significant interaction between the coagulopathy score and survival across the different subgroups. Higher coagulopathy scores in critically ill patients with liver cirrhosis and sepsis were independently associated with poor prognosis. Due to its simplicity and potential predictive value, the coagulopathy score can serve as an effective complement to existing clinical tools for managing critically ill patients with liver cirrhosis and sepsis.